Santhera Gets First Duchenne Drug OKd Under UK Early Access Scheme

Santhera Pharmaceuticals’ Raxone has become the first treatment for Duchenne muscular dystrophy to be OKd under the UK’s early access to medicines scheme. The scheme enables patients to access the treatment ahead of it receiving an EU marketing authorization.